{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:14:50Z","timestamp":1790115290211,"version":"4.0.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Lipoprotein apheresis has been first line therapy for homozygous familial hypercholesterolaemia (FH) and other severe and refractory forms of dyslpidaemia for over 40\u200ayears but the recent advent of novel and potent LDL-lowering compounds necessitates a reappraisal of its role.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>During the past decade a substantial amount of evidence has accumulated describing the effect of LDL-lowering with apheresis and conventional drug therapy upon the cardiovascular outcomes associated with homozygous and statin-refractory heterozygous FH. This has necessitated re-defining the target levels of LDL cholesterol needed to arrest progression of atherosclerosis in these situations. At the same time, evidence has accrued regarding the pathogenicity of raised levels of lipoprotein (a) and the promising role of apheresis in mitigating the adverse effects of the latter. The latest advance in treatment has been the introduction of three classes of novel and potent LDL-lowering compounds in the shape of inhibitors of Propertin convertase subtilisin kexin 9 (PCSK9), microsomal triglyceride transfer protein and angiopoietin-like 3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>These recent developments raise the question of whether these compounds will be used as adjuvants to bolster lipoprotein apheresis in FH homozygotes or whether they will render it obsolete, as is already occurring with PCSK9 inhibitors in FH heterozygotes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000784","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:35:38Z","timestamp":1632530138000},"page":"363-369","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Use of apheresis in the age of new therapies for familial hypercholesterolaemia"],"prefix":"10.1097","volume":"32","author":[{"given":"Gilbert R.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"R1-20250729","first-page":"252","article-title":"Formes homozygotes cutane-tendineuses de xanthomatose hyperchol\u00e9sterol\u00e9mique dans une observation familiale exemplaire. Essai de plasmaph\u00e8r\u00e9se \u00e0 titre de traitment h\u00e9roique","volume":"118","author":"De Gennes","year":"1967","journal-title":"Bull Mem Soc Hop Paris"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(75)92193-5","article-title":"Plasma exchange in the management of homozygous familial hypercholesterolaemia","volume":"1","author":"Thompson","year":"1975","journal-title":"Lancet"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(81)91213-7","article-title":"Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia","volume":"2","author":"Stoffel","year":"1981","journal-title":"Lancet"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11883-019-0787-5","article-title":"Current role of lipoprotein apheresis","volume":"21","author":"Thompson","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2019.09.006","article-title":"Lipoprotein apheresis efficacy, challenges and outcomes: a descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989\u20132017","volume":"290","author":"Pottle","year":"2019","journal-title":"Atherosclerosis"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","article-title":"Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia","volume":"30","author":"Watts","year":"2021","journal-title":"Heart Lung Circ"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1136\/bmj.291.6510.1671","article-title":"Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange","volume":"291","author":"Thompson","year":"1985","journal-title":"Br Med J Clin Res Ed"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"R9-20250729","first-page":"45","article-title":"Fatal myocardial infarction at 4.5\u200ayears in a case of homozygous familial hypercholesterolaemia","volume":"2","author":"Gautschi","year":"2012","journal-title":"JIMD Rep"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/hrt.80.6.583","article-title":"Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia","volume":"80","author":"Rallidis","year":"1998","journal-title":"Heart"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacl.2016.04.006","article-title":"Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry","volume":"10","author":"Alonso","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances","volume":"17","author":"Stefanutti","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/S0021-9258(19)42341-7","article-title":"Binding and degradation of low density lipoproteins by cultured human fibroblasts","volume":"249","author":"Goldstein","year":"1974","journal-title":"J Biol Chem"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0021-9150(00)00371-3","article-title":"The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels","volume":"152","author":"Kroon","year":"2000","journal-title":"Atherosclerosis"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"e13053","DOI":"10.1111\/eci.13053","article-title":"Lipoprotein (a) and low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease","volume":"49","author":"Ma","year":"2019","journal-title":"Eur J Clin Invest"},{"issue":"(Suppl)","key":"R18-20250729","first-page":"1152","article-title":"Plasmapheresis in familial hypercholesterolemia","volume":"9","author":"Thompson","year":"1989","journal-title":"Arteriosclerosis"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0022-2275(20)38106-2","article-title":"Cholesterol turnover in lipid phases of human atherosclerotic plaque","volume":"23","author":"Katz","year":"1982","journal-title":"J Lipid Res"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1567-5688(09)71805-7","article-title":"LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience","volume":"10","author":"Keller","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","article-title":"Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes","volume":"243","author":"Thompson","year":"2015","journal-title":"Atherosclerosis"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2015.01.007","article-title":"Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia","volume":"239","author":"Lefort","year":"2015","journal-title":"Atherosclerosis"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1537-2995.2009.02135.x","article-title":"Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis","volume":"49","author":"Stefanutti","year":"2009","journal-title":"Transfusion"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/eurheartj\/ehx317","article-title":"Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol","volume":"391","author":"Thompson","year":"2018","journal-title":"Eur Heart J"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1744-9987.2008.00574.x","article-title":"Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21\u200ayears","volume":"12","author":"Palcoux","year":"2008","journal-title":"Ther Apher Dial"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.amjcard.2008.06.049","article-title":"Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia","volume":"102","author":"Hudgins","year":"2008","journal-title":"Am J Cardiol"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"key":"R29-20250729","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jacl.2012.03.004","article-title":"Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia","volume":"6","author":"Graesdal","year":"2012","journal-title":"J Clin Lipidol"},{"key":"R30-20250729","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"R31-20250729","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(95)92961-4","article-title":"Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis","volume":"345","author":"Thompson","year":"1995","journal-title":"Lancet"},{"key":"R32-20250729","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/01.CIR.93.10.1826","article-title":"Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis","volume":"93","author":"Kroon","year":"1996","journal-title":"Circulation"},{"key":"R33-20250729","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0021-9150(98)00328-1","article-title":"Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS)","volume":"144","author":"Nishimura","year":"1999","journal-title":"Atherosclerosis"},{"key":"R34-20250729","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"(Suppl 1)","key":"R35-20250729","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11789-017-0089-9","article-title":"The German Lipoprotein Apheresis Registry (GLAR) \u2212 almost 5\u200ayears on","volume":"12","author":"Schettler","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"R36-20250729","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.transci.2018.07.015","article-title":"Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study","volume":"57","author":"Bigazzi","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"R37-20250729","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"R38-20250729","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"R39-20250729","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"key":"R40-20250729","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"R41-20250729","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pathol.2018.10.016","article-title":"Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)","volume":"51","author":"Waldmann","year":"2019","journal-title":"Pathology"},{"key":"R42-20250729","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"key":"R43-20250729","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagn\u00e9","year":"2002","journal-title":"Circulation"},{"key":"R44-20250729","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"R45-20250729","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R46-20250729","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"R47-20250729","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH Trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R48-20250729","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jacc.2020.05.033","article-title":"PCSK9 inhibitors for homozygous familial hypercholesterolemia: useful but seldom sufficient","volume":"76","author":"Thompson","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R49-20250729","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"R50-20250729","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Eng J Med"},{"key":"R51-20250729","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"key":"R52-20250729","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"key":"R53-20250729","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","article-title":"Marked plaque regression in homozygous familial hypercholesterolemia","volume":"327","author":"Reeskamp","year":"2021","journal-title":"Atherosclerosis"},{"key":"R54-20250729","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.atherosclerosis.2017.09.011","article-title":"Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis","volume":"265","author":"Kawashiri","year":"2017","journal-title":"Atherosclerosis"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:09:13Z","timestamp":1753826953000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000784","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}